A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER. Ma, C. X., Luo, J., Freedman, R. A., Pluard, T., Nangia, J., Lu, J., Valdez-Albini, F., Cobleigh, M., Jones, J., Lin, N. U., Winer, E., Marcom, P., Thomas, S., Anderson, J., Haas, B., Hamann, K. M., Bryce, R., Lalani, A. S., Carey, L., Goetz, M., Gao, F., Kimmick, G., Pegram, M., Ellis, M. J., Bose, R. AMER ASSOC CANCER RESEARCH. 2021

View details for Web of Science ID 000680263501009